Look for:

Our offer for

BIOCARTIS GROUP NV


ISIN:
BE0974281132
WKN:
-
2023/09/25 08:11:21
Price
0.2585 EUR
Difference -4.26% (-0.01)

General attributes

ISINBE0974281132
Symbol-
ExchangeDuesseldorf
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)27 EUR
BenchmarkBEL 20 INDEX

Market data

Bid (Bid size)-
Ask (Ask size)-
Open0.2585 EUR
High0.2585 EUR
Low0.2585 EUR
Close (prev. day)0.27 EUR
VWAP-
Volume (pcs)0
Trading volume0.00
Number of trades1
Last size0

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Company report: BIOCARTIS GROUP NVPDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2023/09/25 08:11:21
Price
0.2585 EUR
Difference -4.26% (-0.01)

General attributes

ISINBE0974281132
Symbol-
ExchangeDuesseldorf
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)27 EUR
BenchmarkBEL 20 INDEX

Market data

Bid (Bid size)-
Ask (Ask size)-
Open0.2585 EUR
High0.2585 EUR
Low0.2585 EUR
Close (prev. day)0.27 EUR
VWAP-
Volume (pcs)0
Trading volume0.00
Number of trades1
Last size0

Performance and Risk

6m1Y3Y
Perf (%)-58.17%-69.10%-
Perf (abs.)-0.36-0.58-
Beta0.00-0.010.74
Volatility74.1077.82-
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)0.2685 EUR (0)
Ø price 30 days | Ø volume 30 days (pcs.)0.3012 EUR (0)
Ø price 100 days | Ø volume 100 days (pcs.)0.3839 EUR (0)
Ø price 250 days | Ø volume 250 days (pcs.)0.5787 EUR (0)
YTD High | date0.7380 EUR (2023/04/14)
YTD Low | date0.2555 EUR (2023/09/22)
52 Weeks High | date1.2369 EUR (2022/10/19)
52 Weeks Low | date0.2555 EUR (2023/09/22)

All listings for BIOCARTIS GROUP NV

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Stuttgart2023/09/2508:070.2595 EUR0.003
London Stock Exchange European Trade Reporting2023/09/2517:300.299 EUR0.002
Frankfurt2023/09/2508:080.2595 EUR0.001
FINRA other OTC Issues2022/12/0919:400.66 USD0.001
Euronext Brussels2023/09/2217:350.29 EUR0.0372
Duesseldorf2023/09/2508:110.2585 EUR0.001
Berlin2023/09/2508:220.2895 EUR0.001

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=138579&ID_TYPE_IMAGE_LOGO=2

Contact Details

BIOCARTIS GROUP NV
- -
Generaal de Wittelaan 11B - 2800 Mechelen
Telefon: +32-1-563-26-00
Fax: +
E-mail: info@biocartisgroupnv.be

PDF Downloads

Company report: BIOCARTIS GROUP NVPDF Download

Company Profile

Biocartis Group NV engages in the development of personalized medicine for patients around the world. It also focuses on developing and commercializing oncology tests. The company was founded by Philippe Renaud, Nader Donzel, and Rudi Pauwels in July 2007 and is headquartered in Mechelen, Belgium.

Members of Management Board

Roger MoodyChairman of Managing Board
George CardozaMember of Executive Committee
Piet HouwenMember of Executive Committee

Board of directors

Herman VerrelstChairman of Supervisory Board
Bryan DeChairoMember of Supervisory Board
Christian ReinaudoMember of Supervisory Board
Christine KuslichMember of Supervisory Board
Ann-Christine M. SundellMember of Supervisory Board
Luc GijsensMember of Supervisory Board





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer